DrugPatentWatch Database Preview
Drugs in Development Information for CC-223
» See Plans and Pricing
What is the drug development status for CC-223?
CC-223 is an investigational drug.
There have been 5 clinical trials for CC-223.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2010.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lymphoma, Large B-Cell, Diffuse, and Lymphoma, B-Cell. The leading clinical trial sponsors are Celgene Corporation and [disabled in preview].
Summary for CC-223
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 54 |
| WIPO Patent Applications | 27 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2010-07-01) |
| Vendors | 35 |
Recent Clinical Trials for CC-223
| Title | Sponsor | Phase |
|---|---|---|
| Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma | Celgene Corporation | Phase 1 |
| CC-223 and Ketoconazole Drug-Drug Interaction Study | Celgene Corporation | Phase 1 |
| A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects | Celgene Corporation | Phase 1 |
Clinical Trial Summary for CC-223
Top disease conditions for CC-223
Top clinical trial sponsors for CC-223
US Patents for CC-223
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
